Press Release

- Phase 1 safety study of NTS-104 is initiated in healthy volunteers - - Compound is being developed for stroke and other Central Nervous System (CNS) injuries -  ATLANTA, GA,... read more →

- Marc de Somer, MD, ScD, MPH, MSc, MBA, appointed Chief Medical Officer - - Martin Rabe, MSc, appointed Executive Vice President of Regulatory Affairs and Quality Assurance -  ATLANTA,... read more →

Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI ATLANTA, Oct. 25, 2021 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company... read more →

Download PDF › Poster presentation at 39th Annual Symposium of the National Neurotrauma Society ATLANTA, Ga., June 27, 2022 – NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing... read more →

ATLANTA, GA, June 7, 2022 – NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the... read more →

FOR IMMEDIATE RELEASE (PDF DOWNLOAD) -NTS Exercises Option after Conducting Preclinical Research on Neuroactive Small Molecule- ATLANTA, Ga., December 11, 2019 – NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company,... read more →

FOR IMMEDIATE RELEASE (PDF DOWNLOAD) — NeuroTrauma Sciences Announces Expansion of Its Executive Leadership Team — — Judith Hedstrom appointed to expanded Chief Operating Officer role — — Anthony... read more →

— One-of-a-kind international study aims to advance care for patients with traumatic brain injuries — ATLANTA, GA, May 11, 2021 – NeuroTrauma Sciences,... read more →